Ghassan K. Abou‐Alfa - Researcher Profile

Publications

2 shown

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , Tim Meyer , Ann‐Lii Cheng +19 more

Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than plac...

2018 New England Journal of Medicine 2228 citations

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa , Vaibhav Sahai , Antoine Hollebecque +16 more

Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, ...

2020 The Lancet Oncology 1455 citations

Frequent Co-Authors

Lorenza Rimassa

Baek‐Yeol Ryoo

Asan Medical Center

İrfan Çiçin

Trakya University

Researcher Info

h-index: 2
Publications: 2
Citations: 3,683
Institution: Cornell University

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-1522-8054

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.